Cantor Fitzgerald Reaffirms “Overweight” Rating for Agios Pharmaceuticals (NASDAQ:AGIO)

Cantor Fitzgerald reissued their overweight rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report released on Wednesday,Benzinga reports.

Other equities analysts also recently issued reports about the stock. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Royal Bank of Canada lifted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank increased their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Raymond James reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Finally, Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Stock Down 4.7 %

Shares of AGIO stock traded down $1.83 during trading hours on Wednesday, hitting $37.19. 164,649 shares of the company’s stock were exchanged, compared to its average volume of 719,730. The firm has a 50 day moving average of $50.06 and a two-hundred day moving average of $46.78. Agios Pharmaceuticals has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The firm has a market cap of $2.12 billion, a P/E ratio of 3.27 and a beta of 0.80.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals during the second quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the period. CWM LLC lifted its holdings in shares of Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $146,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.